PDS Biotechnology Corporation (PDSB) — Financial statements
Income statement, balance sheet, and cash flow for PDS Biotechnology Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.06↑4.3% | 0.06 | 0.00 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -0.06↓4.3% | -0.06 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 19↓15.7% | 23↓18.7% | 28↓5.7% | 29↑161.5% | 11 | |
| General & Administrative Expenses | 13 | 0.00↓100.0% | 15↑22.7% | 12↑20.2% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.26 | 0.00 | 0.00 | |
| SG&A Expenses | 13↓8.6% | 14↓10.4% | 15↑24.8% | 12↑20.2% | 10 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 32↓13.0% | 36↓15.8% | 43↑3.3% | 42↑94.4% | 21 | |
| Total Costs & Expenses | 32↓13.2% | 36↓15.6% | 43↑3.3% | 42↑94.4% | 21 | |
| Operating Results | ||||||
| Operating Income | -32↑13.2% | -36↑15.6% | -43↓3.3% | -42↓94.4% | -21 | |
| Depreciation & Amortization | 0.02↓63.5% | 0.06↑4.3% | 0.06↑66558.1% | 0.00↓98.4% | 0.01 | |
| EBITDA | -30↑10.2% | -34↑15.8% | -40↑1.6% | -41↓90.1% | -21 | |
| EBIT | -30↑10.3% | -34↑15.8% | -40↑1.5% | -41↓90.1% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | -4↓91.0% | -2↓65.6% | -1↓242.0% | -0.38↓8866.7% | 0.00 | |
| Interest Income | 1↓51.6% | 3↓13.4% | 3↑210.4% | 0.94↑21418.2% | 0.00 | |
| Interest Expense | 5↑14.2% | 5↑11.1% | 4↑219.4% | 1 | 0.00 | |
| Non-Operating Income | -1↑51.6% | -3↑13.4% | -3↓210.4% | -0.94↓21418.2% | -0.00 | |
| Other Income / Expenses | -4↓90.9% | -2↓65.6% | -1↓241.7% | -0.38↓8874.5% | 0.00 | |
| Income Before Tax | -36↑7.3% | -38↑13.2% | -44↓5.5% | -42↓96.2% | -21 | |
| Income Tax Expense | -1↓34.6% | -0.87↑38.2% | -1↓17.3% | -1↑73.5% | -5 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↑8.3% | -38↑12.4% | -43↓5.1% | -41↓141.5% | -17 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↑8.3% | -38↑12.4% | -43↓5.1% | -41↓141.5% | -17 | |
| Bottom-Line Net Income | -34↑8.3% | -38↑12.4% | -43↓5.1% | -41↓141.5% | -17 | |
| EPS (Basic) | -0.74↑28.2% | -1.03↑25.9% | -1.39↑2.8% | -1.43↓116.7% | -0.66 | |
| EPS (Diluted) | -0.74↑28.2% | -1.03↑25.9% | -1.39↑2.8% | -1.43↓116.7% | -0.66 | |
| Weighted Average Shares | 46↑27.2% | 36↑17.8% | 31↑8.2% | 29↑11.7% | 26 | |
| Weighted Average Diluted Shares | 46↑27.2% | 36↑17.8% | 31↑8.2% | 29↑11.7% | 26 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.